Silence Therapeutics PLC (SLN)
13.98
-1.30
(-8.54%)
USD |
NASDAQ |
Nov 14, 16:00
13.98
0.00 (0.00%)
After-Hours: 20:00
Silence Therapeutics Net Income (Quarterly): -19.63M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -19.63M |
March 31, 2024 | -2.380M |
December 31, 2023 | -17.90M |
September 30, 2023 | -10.45M |
June 30, 2023 | -13.02M |
March 31, 2023 | -12.40M |
December 31, 2022 | -16.18M |
September 30, 2022 | -8.360M |
Date | Value |
---|---|
June 30, 2022 | -15.01M |
March 31, 2022 | -10.31M |
December 31, 2021 | -12.72M |
September 30, 2021 | -13.69M |
June 30, 2021 | -16.25M |
March 31, 2021 | -11.61M |
December 31, 2020 | -16.41M |
September 30, 2020 | -11.73M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-19.63M
Minimum
Jun 2024
-2.380M
Maximum
Mar 2024
-13.00M
Average
-12.87M
Median
Net Income (Quarterly) Benchmarks
NuCana PLC | -8.826M |
TC BioPharm (Holdings) PLC | -4.213M |
Biodexa Pharmaceuticals PLC | -- |
Adaptimmune Therapeutics PLC | 69.52M |
Verona Pharma PLC | -42.96M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 0.7545M |
Total Expenses (Quarterly) | 23.87M |
EPS Diluted (Quarterly) | -0.4201 |
Enterprise Value | 525.86M |
Gross Profit Margin (Quarterly) | -341.1% |
Profit Margin (Quarterly) | -2.60K% |
Earnings Yield | -8.73% |
Normalized Earnings Yield | -8.732 |